Company Profile

Adepthera LLC
Profile last edited on: 10/22/22      CAGE: 6M1S1      UEI: QDWUGUNKHMT5

Business Identifier: Hormone-based biopharmaceuticals
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

3353 Alma Street Suite 245
Palo Alto, CA 94306
   (650) 799-3496
Location: Single
Congr. District: 18
County: Santa Clara

Public Profile

Adepthera LLC develops endocrine-based biopharmaceuticals. Under the direction of Stanford University School of Medicine professor Dr. Sheauyu Teddy Hsu, the company seeks to develop Hsu's research on the therapeutic potential for hormones in human health, including applications in treating life-threatening cardiovascular, developmental, and metabolic diseases. The company is focusing on preclinical and clinical development of a group of novel hormonal drug candidates.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $338,152
Project Title: Development of a Treatment-Resistant Hypertension (RHTN) Depot Therapeutics
2019 1 NIH $248,910
Project Title: Development of a Novel Anti-Migraine Therapeutics
2017 1 NIH $290,425
Project Title: Novel Therapeutics for Endothelial Dysfunction
2017 1 NIH $296,941
Project Title: Novel Nanomedicine for Treatment-Resistant Hypertension (Rhtn)
2015 1 NIH $299,299
Project Title: A Hormonal Therapy for Bronchopulmonary Dysplasia

Key People / Management

  Sheau-Yu Teddy Hsu -- Managing Director

Company News

There are no news available.